Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program.

Unlabelled:  Background. Daclatasvir and asunaprevir dual therapy is approved for the treatment of HCV genotype 1b infection in several countries.

Aim: To evaluate the efficacy and safety of daclatasvir and asunaprevir dual therapy in Turkish patients.